In this video, Arshad Khanani, MD, speaks about one of his presentations at the virtual Euretina congress in which he reported the results of an analysis of retinal fluid and visual acuity outcomes in the Archway trial.
Archway was a phase 3 trial comparing the Port Delivery System (PDS, Genentech) with refill every 24 weeks and the gold standard of monthly intravitreal ranibizumab injection in patients with neovascular age-related macular degeneration.